Table 1 Characteristics of the FibroTest diagnostic studies for the staging of hepatic fibrosis in patients with chronic liver disease
From: Meta-analyses of FibroTest diagnostic value in chronic liver disease
First author [ref] | Number Patients | Methodology | Age | Stage Prevalence | AUROC SE | F0 (%) | F1 (%) | F2 (%) | F3 (%) | F4 (%) | DANA | Size mm | Independent | Guidelines and fresh | Biopsy FT median days | High risk profile $ (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HCV n = 20 | ||||||||||||||||
Imbert-1, 2001 (21) | 189 | Prospective Single center Training cohort | 47 | F2F3F4 0.38 | 0.84 0.03 | 36 (18) | 91 (44) | 40 (20) | 18 (9) | 20 (10) | 2.03 | 16 | No | Yes | 0 | NA |
Imbert-2, 2001 (21) | 134 | Prospective Single center Validation cohort | 48 | F2F3F4 0.45 | 0.87 0.03 | 20 (15) | 54 (40) | 28 (21) | 10 (7) | 22 (16) | 2.16 | 16 | No | Yes | 0 | NA |
Poynard-1, 2001 (22) | 299 | Retrospective Randomized trial Multicenter | 41 | F3F4 Knodell 0.36 | 0.74 0.03 | 60 (20) | 133 (44) | 56** (17) | 55 (17) | 5 (2) | 1.42 | NA | Mixed | Yes | NA | NA |
Poynard-2, 2003 (23) | 352 | Retrospective Randomized trial Multicenter Before treatment | 45 | F2F3F4 0.39 | 0.73 0.03 | 6 (2) | 206 (59) | 63 (18) | 32 (9) | 32 (9) | 1.71 | 17 | Mixed | No | 137 | 0 (0) |
Poynard-3, 2003 (23) | 352 | Retrospective Randomized trial Multicenter After treatment | 47 | F2F3F4 0.32 | 0.77 0.03 | 15 (4) | 222 (63) | 64 (18) | 25 (7) | 26 (10) | 1.73 | 17 | Mixed | No | 12 | 0 (0) |
Rossi, 2003 (24) | 125 | Prospective Multicenter | 40 | F2F3F4 0.38 | 0.74 0.05 | 25 (20) | 52 (42) | 26 (21) | 13 (10) | 9 (7) | 1.95 | NA | Yes | No | 0 | 0 (0) |
Myers-1, 2003 (25) | 130 | Retrospective Single center HCV-HIV Co-infection | 38 | F2F3F4 0.45 | 0.86 0.04 | 17 (13) | 55 (42) | 22 (17) | 19 (15) | 17 (13) | 2.15 | NA | No | Yes | < 180 | NA |
Castera, 2005 (26) | 183 | Prospective Single center | 51 | F2F3F4 0.38 | 0.84 0.03 | 0 (0) | 47 (26) | 53 (29) | 37 (20) | 46 (25) | 1.95 | 17 | Yes | Yes | 0 | NA |
Cales-2, 2005 (7) | 120 | Prospective Single center Validation cohort | 44 | F2F3F4 0.48 | 0.86 0.06 | 20 (17) | 43 (36) | 28 (3) | 14 (12) | 15 (13) | 2.09 | 21 | Yes | No | < 7 | NA |
Coletta, 2005 (27) | 40 | Prospective Multicenter PNALT | 44 | F2F3F4 0.35 | NA | 3 (8) | 23 (58) | 9 (23) | 5 (13) | 0 (0) | 1.47 | 20 | Yes | NA | 180 | NA |
Varaut-1, 2005 (28) | 50 | Retrospective Single center Dialysis patients | 48 | F2F3F4 0.42 | 0.53 0.04 | 1 (2) | 28 (56) | 11 (22) | 8 (16) | 2 (4) | 1.61 | 19 | Yes | No | < 180 | 2 (4) |
Varaut-2, 2005 (28) | 60 | Retrospective Single center Kydney recipients | 44 | F2F3F4 0.44 | 0.71 0.04 | 10 (21) | 21 (35) | 17 (28) | 10 (16) | 2 (3) | 1.84 | 19 | Yes | No | < 180 | 2 (3.3) |
Halfon, 2006 (29) | 504 | Prospective Multicenter | 45 | F2F3F4 0.45 | 0.79 0.02 | 58 (12) | 216 (43) | 110 (22) | 91 (18) | 29 (6) | 1.87 | 15 | Yes | Yes | 0 | 15 (3) |
Sebastiani-1, 2006 (30) | 65 | Prospective PNALT | 45 | F2F3F4 0.39 | 0.71 0.04 | 18 (27) | 22 (34) | 12 (19) | 6 (9) | 7 (11) | 2.21 | 18 | Yes | Yes | 0 | Excluded |
Sebastiani-2, 2006 (30) | 125 | Prospective EALT | 50 | F2F3F4 0.71 | 0.81 0.03 | 6 (5) | 30 (24) | 53 (42) | 15 (12) | 21 (17) | 1.83 | 18 | Yes | Yes | 0 | Excluded |
Wilson, 2006 * (31) | 115 | Retrospective Multicenter 30% HIV | 42 | F2F3F4 0.38 | 0.74 0.05 | 39 (33) | 36 (30) | 33 (28) | 8 (7) | 3 (3) | 1.87 | 11 | Yes | No | Contemporaneous | NA |
Sene, 2006 (32) | 138 | Prospective Single center Cryoglobulinemia Vasculitis | 58 | F2F3F4 0.47 | 0.83 0.03 | 37 (27) | 36 (26) | 30 (22) | 16 (12) | 19 (14) | 3.05 | 18 | No | Yes | < 60 | 11 (8) |
Halfon-2, 2007 (36) | 158 | Prospective Single center | 41 | F2F3F4 | 0.79 0.03 | 6 (4) | 103 (65) | 34 (22) | 13 (8) | 2 (1) | 1.38 | 21 | Yes | Yes | 0 | NA |
Leroy, 2007 (37) | 180 | Prospective Single center | 44 | F2F3F4 | 0.84 0.03 | 15 (8) | 74 (41) | 40 (22) | 26 (14) | 25 (14) | 2.00 | 23 | Yes | Yes | 0 | NA |
Grigorescu, 2007 (39) | 206 | Single center | 47 | F2F3F4 | 0.78 0.02 | 16 (8) | 60 (29) | 70 (34) | 44 (21) | 16 (8) | 1.80 | NA | Yes | Yes | NA | Excluded |
HBV n = 4 | ||||||||||||||||
Myers-2 (3) | 209 | Prospective and (42) Retrospective (167) | 39 | F2F3F4 0.29 | 0.78 0.04 | 76 (36) | 72 (34) | 32 (15) | 10 (5) | 19 (9) | 2.31 | 18 | No | Yes | 1 | NA |
Poynard-4, 2005 (4) | 214 | Prospective | 40 | F2F3F4 0.67 | 0.77 0.03 | 14 (8) | 53 (25) | 119 (24) | 55 (26) | 40 (19) | 2.17 | NA | Mixed | Yes | 150 | 7 (3.2) |
Sebastiani-3, 2007 (33) | 110 | Prospective | 43 | F2F3F4 | 0.85 0.04 | 15 (14) | 20 (18) | 40 (36) | 13 (12) | 22 (20) | 2.19 | 17 | Yes | Yes | 0 | Excluded |
Poynard-5, 2007 (34) | 924 | Retrospective | 39 | F2F3F4 | 0.76 0.02 | 21 (2) | 596 (65) | 160 (17) | 69 (7) | 78 (8) | 1.77 | 13 | Mixed | Yes | 90 | 80 excluded (8) |
ALD n = 2 | ||||||||||||||||
Naveau, 2005 (5) | 221 | Prospective One center | 47 | F2F3F4 0.64 | 0.84 003 | 16 (7) | 65 (29) | 48 (22) | 24 (11) | 68 (31) | 2.34 | 15 | Mixed | Yes | 9 | 4 (1.8) |
Thabut, 2006 (35) | 208 | Prospective Two centers | 51 | F2F3F4 | 0.91 0.02 | 10 (5) | 25 (12) | 21 (10) | 17 (8) | 136 (65) | 2.98 | 12 | Mixed | Yes | 0 | 15 (7.2) |
NAFLD n = 2 | ||||||||||||||||
Ratziu-1, 2006 (8) | 170 | Prospective | 53 | F2F3F4 0.24 | 0.86 0.03 | 77 (45) | 54 (31) | 20 (12) | 11 (7) | 9 (5) | 2.30 | 20 | No | Yes | 0 | 5 (2.9) |
Ratziu-2, 2006 (8) | 97 | Prospective | 49 | F2F3F4 0.15 | 0.75 0.04 | 26 (27) | 40 (41) | 15 (15) | 12 (12) | 4 (4) | 2.04 | 18 | Yes | Yes | 0 | 2 (2) |
Mixed n = 3 | ||||||||||||||||
Cales1, 2005 (7) | 478 | Prospective Single center HCV, HBV, ALD | 45 | F2F3F4 0.59 | 0.82 0.03 | 28 (6) | 170 (36) | 120 (25) | 57 (12) | 102 (21) | 2.08 | 18 | Yes | No | < 7 | NA |
Callewaert, 2004 (6) | 106 | Prospective HCV and ALD | NA | F4 0.29 | 0.89 0.04 | 0 (0) | 28 (26) | 20 (19) | 10 (9) | 48 (45) | 2.73 | NA | Yes | Yes | NA | NA |
Coco, 2007 (38) | 164 | Prospective HCV and HBV | 50 | F2F3F4 | 0.89 0.05 | 29 (18) | 33 (20) | 13 (8) | 6 (4) | 83 (51) | 3.15 | 25 | Yes | Yes | 90 | NA |